MYOV News and Press, Myovant Sciences Ltd. From 02/17/21

LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to pla...

Six women reflect on their period experiences and journeys to self-advocacy in new video series Video stories and additional information about “Voices of Periods” now available on femaleforwardtogether.com RED BANK, N.J. and BASEL, Switzerland, Feb....

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q3 2020 Earnings Call Feb 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q3 2020 Earnings Call Transcript

Myovant Sciences Ltd. (MYOV) Q3 2020 Earnings Conference Call February 11, 2021, 08:30 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations Dave Marek - Chief Executive Officer Frank Karbe - President & Chief Financial Officer Adele Gulfo - Interim Chief Business a...

Myovant Sciences (MYOV): Q4 GAAP EPS of -$0.82 beats by $0.03.Revenue of $1.38M misses by $0.79M.Cash, cash equivalents, marketable securities, and committed amounts available under the Sumitomo Dainippon Pharma Loan Agreement totaled $832.1 million as of December 31, 2020, and consisted...

ORGOVYX™ (relugolix) approved by the U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announced collabora...

Neurocrine had already informed investors about weak fourth quarter Ingrezza sales, but AbbVie sales of Orilissa and Oriahnn were weak again, and Ongentys missed expectations as well. Management is upping its marketing spend, likely focusing on getting docs more comfortable with presc...

Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager. Ingrezza sales have been knocked off stride by COVID-19, and it remains to be seen how quickly the company can regain the sort of growth that...

BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal...

Myovant Sciences (MYOV) and Pfizer (PFE) have announced data from Phase 3 SPIRIT long-term extension study evaluating relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in women with endometriosis.84.8% and 73.3% of women reported clinically meaningful reductions in d...